Company
PharmatrophiX
Alzheimer's and Neurodegenerative diseases damage brain connections. PharmatrophiX developing drug targets synaptic resilience.
Also known as PharmatrophiX, Inc
- Business model
- B2B
- Legal name
- PharmatrophiX, Inc
Claim, correct or request removal
Record updated 29 September 2026
About
PharmatrophiX is focused on the development of disease-modifying small molecule drugs, discovering & developing small molecule Neurotrophin pathway modulators.
Funding snapshot
- Total raised
- $11.5MSEC form D sum, as of 2026-09-29Source (opens in a new tab)
- Latest round
- Round, $10.3M2014-06-27
Funding rounds
- Round, 2014
- $10.3M2014-06-27, SEC form D sold, 15 investors
- Round, 2013
- $250K2013-10-11, SEC form D sold, 1 investor
- Round, 2012
- $800K2012-08-29, SEC form D sold, 3 investors
- Round, 2010
- $180K2010-03-02, SEC form D sold, 1 investor
Loading relationship preview